Literature DB >> 10947018

Most important lymph node information in gastric cancer: multivariate prognostic study.

Y Adachi1, N Shiraishi, T Suematsu, A Shiromizu, K Yamaguchi, S Kitano.   

Abstract

BACKGROUND: In gastric cancer, the level and number of lymph node metastases is useful for predicting survival, and there are several staging systems for lymph node metastasis. The aim of this study was to compare the several lymph node classifications and to clarify the most important lymph node information associated with prognosis using multivariate analysis.
METHODS: A total of 106 patients with histologically node-positive gastric cancer treated by radical gastrectomy and extended lymph node dissection (D2, D3) were studied. The level of lymph node metastasis was categorized simply as Level I nodes (perigastric, No.1-6), Level II nodes (intermediate, No.7-9), and Level III nodes (distant, No.10-16), irrespective of the tumor location. The Level II nodes included lymph nodes along the left gastric artery, common hepatic artery, and celiac trunk.
RESULTS: Overall 5-year survival rate was 51%. Univariate analysis showed that 5-year survival rate was significantly influenced by the level of positive nodes (P < .01), total number of positive nodes (P < .01), number of positive Level I nodes (P < .01), and number of positive Level II nodes (P < .01), in addition to the tumor location (P < .05), tumor size (P < .05), gross type (P < .01), and depth of wall invasion (P < .01). Of these, independent prognostic factors associated with 5-year survival rate were the number of positive Level II nodes (0-1 vs. > or =2) (62% vs. 19%, P < .01) and the depth of wall invasion (within vs. beyond muscularis) (79% vs. 43%, P < .01).
CONCLUSIONS: Among several staging systems for lymph node metastases, the number of positive Level II nodes provided the most powerful prognostic information in patients with node-positive gastric cancer. When there were two or more metastases in the Level II nodes, prognosis was poor even after D2 or D3 gastrectomy.

Entities:  

Mesh:

Year:  2000        PMID: 10947018     DOI: 10.1007/s10434-000-0503-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Curcumin suppresses lymphatic vessel density in an in vivo human gastric cancer model.

Authors:  Wei Da; Jinshui Zhu; Long Wang; Qun Sun
Journal:  Tumour Biol       Date:  2015-02-10

2.  Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence.

Authors:  Jingyu Deng; Han Liang; Dan Sun; Rupeng Zhang; Hongjie Zhan; Xiaona Wang
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

3.  Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.

Authors:  Xue-Feng Ni; Chang-Ping Wu; Jing-Ting Jiang
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?

Authors:  J Zhang; S Zou; R Luo; Z Zhu; Z Wang; H Xu; B Huang
Journal:  Clin Transl Oncol       Date:  2019-04-11       Impact factor: 3.405

5.  The anatomical configuration of the splenic artery influences suprapancreatic lymph node dissection in laparoscopic gastrectomy: analysis using a 3D volume rendering program.

Authors:  Chunchao Zhu; Seong-Ho Kong; Tae-Han Kim; Shin-Hoo Park; Rene Ronson G Ang; Michele Diana; Luc Soler; Yun-Suhk Suh; Hyuk-Joon Lee; Jacques Marescaux; Hui Cao; Han-Kwang Yang
Journal:  Surg Endosc       Date:  2018-05-03       Impact factor: 4.584

6.  Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.

Authors:  Atsuo Shida; Shuichi Fujioka; Katsutoshi Kobayashi; Yoshio Ishibashi; Hiroshi Nimura; Norio Mitsumori; Katsuhiko Yanaga
Journal:  Int J Clin Oncol       Date:  2006-02       Impact factor: 3.402

7.  Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer.

Authors:  Fusun Ozmen; M Mahir Ozmen; Evren Ozdemir; Munevver Moran; Selda Seçkin; Dicle Guc; Ergun Karaagaoglu; Emin Kansu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

8.  The prognostic value of β-catenin and LEF-1 expression in patients with operable gastric carcinoma.

Authors:  Serap Kaya; Mahmut Gumus; Yesim Gurbuz; Devrim Cabuk; Ozgur Acikgoz; Suleyman Temiz; Kazim Uygun
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

9.  Comparison of colorectal and gastric cancer: survival and prognostic factors.

Authors:  Bijan Moghimi-Dehkordi; Azadeh Safaee; Mohammad R Zali
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

10.  Impact of the latest TNM classification for gastric cancer: retrospective analysis on 94 D2 gastrectomies.

Authors:  Domenico D'Ugo; Fabio Pacelli; Roberto Persiani; Vito Pende; Andrea Ianni; Valerio Papa; Giovanni Battista Doglietto; Aurelio Picciocchi
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.